Herriot Tabuteau, Chief Executive Officer at Axsome Therapeutics, Inc. (AXSM), sold 125,760 shares at $117.37 ($14.7M) on 2025-09-15, disclosed to the SEC on 2025-09-16.
Scheduled sale ($14.7M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $118.96 | 27,907 | $3.3M | 22.5% |
| 2 | $118.96 | 27,907 | $3.3M | 22.5% |
| 3 | $117.37 | 15,254 | $1.8M | 12.2% |
| 4 | $117.37 | 15,254 | $1.8M | 12.2% |
| 5 | $114.19 | 19,719 | $2.3M | 15.3% |
| 6 | $114.19 | 19,719 |
| $2.3M |
| 15.3% |
| Total | $117.08 avg | 125,760 | $14.7M | 100% |
| Filing → |
| AXSM | SELL | 2026-06-09 | $12.0M | — | Filing → |
| AXSM | SELL | 2026-02-02 | $6.0M | — | Filing → |
| AXSM | SELL | 2026-01-07 | $23.9M | — | Filing → |